Market Research Reports and Industry Reports

Anacor Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Summary

Anacor Pharmaceuticals Inc (Anacor) is a biopharmaceutical company that discovers, develops and markets small molecule therapeutics based on its boron chemistry platform. The companys marketed products include a topical solution which is an oxaborole antifungal that is used for the topical treatment of onychomycosis of the toenails. Its lead pipeline candidates encompass a non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor for the treatment of mild-to-moderate atopic dermatitis and psoriasis; and an antibiotic for the potential treatment of infections caused from gram-negative bacteria. Anacors boron chemistry platform is used to treat diseases in animals caused due to bacteria, fungi and parasites. It out-licensed three investigational compounds: indication targeted at the treatment of an animal health to Eli Lilly and Company; indication for the treatment of human African trypanosomiasis to Drugs for Neglected Diseases; and indication targeted at the treatment of tuberculosis to GlaxoSmithKline LLC. Anacor is headquartered in Palo Alto, California, the US.

Anacor Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Anacor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Anacor Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Anacor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Anacor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Anacor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Anacor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Anacor Pharma Amends Co-Marketing Agreement with Sandoz for Kerydin 10
Anacor Pharma Ammends its Research Agreement With Bill & Melinda Gates Foundation 12
Anacor Pharma Amends And Expands Research Collaboration With GlaxoSmithKline 13
Anacor Pharma And Medicines For Malaria Venture Extend Co-Development Agreement For AN3661 15
iOWH Enters Into Research Agreement With Anacor Pharma 16
Anacor Pharma Enters Into Research And Development Agreement With Medicis Pharma 17
Equity Offering 18
Anacor Pharma Files Registration Statement For Public Offering Of Securities For Up To US$50 Million 18
Anacor Pharma Completes Public Offering Of Common Stock For US$23 Million 19
Anacor Pharma Completes Public Offering Of Common Stock For US$24 Million 20
Anacor Pharma Completes Public Offering Of Common Stock For US$21.5 Million 21
Debt Offering 23
Anacor Pharma Raises USD287.5 Million in Private Placement of 2% Notes Due 2023 23
Anacor Pharma Raises USD82.5 Million Private Placement of Notes Due 2021 25
Anacor Pharma Raises USD8 Million in Private Placement of Notes Due 2021 27
Acquisition 29
Pfizer Acquires Anacor Pharma for USD5.2 Billion 29
Anacor Pharmaceuticals Inc - Key Competitors 31
Anacor Pharmaceuticals Inc - Key Employees 32
Anacor Pharmaceuticals Inc - Locations And Subsidiaries 33
Head Office 33
Recent Developments 34
Financial Announcements 34
May 10, 2016: Anacor Pharmaceuticals Reports First Quarter 2016 Financial Results 34
Feb 29, 2016: Anacor Pharmaceuticals Reports 2015 Fourth Quarter and Year-End Financial Results 36
Appendix 38
Methodology 38
About GlobalData 38
Contact Us 38
Disclaimer 38

List Of Tables

List of Tables
Anacor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 2
Anacor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Anacor Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Anacor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Anacor Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Anacor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Anacor Pharma Amends Co-Marketing Agreement with Sandoz for Kerydin 10
Anacor Pharma Ammends its Research Agreement With Bill & Melinda Gates Foundation 12
Anacor Pharma Amends And Expands Research Collaboration With GlaxoSmithKline 13
Anacor Pharma And Medicines For Malaria Venture Extend Co-Development Agreement For AN3661 15
iOWH Enters Into Research Agreement With Anacor Pharma 16
Anacor Pharma Enters Into Research And Development Agreement With Medicis Pharma 17
Anacor Pharma Files Registration Statement For Public Offering Of Securities For Up To US$50 Million 18
Anacor Pharma Completes Public Offering Of Common Stock For US$23 Million 19
Anacor Pharma Completes Public Offering Of Common Stock For US$24 Million 20
Anacor Pharma Completes Public Offering Of Common Stock For US$21.5 Million 21
Anacor Pharma Raises USD287.5 Million in Private Placement of 2% Notes Due 2023 23
Anacor Pharma Raises USD82.5 Million Private Placement of Notes Due 2021 25
Anacor Pharma Raises USD8 Million in Private Placement of Notes Due 2021 27
Pfizer Acquires Anacor Pharma for USD5.2 Billion 29
Anacor Pharmaceuticals Inc, Key Competitors 31
Anacor Pharmaceuticals Inc, Key Employees 32

Anacor Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Anacor Pharmaceuticals Inc (Anacor) is a biopharmaceutical company that discovers, develops and markets small molecule therapeutics based on its boron chemistry platform. The companys marketed products include a topical solution

USD 250View Report

Anacor Pharmaceuticals Inc (ANAC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile.

Anacor Pharmaceuticals Inc (Anacor) is a biopharmaceutical company that discovers, develops and markets small molecule therapeutics based on its boron chemistry platform. The companys marketed products include a topical solution

USD 250View Report

Dova Pharmaceuticals Inc (DOVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Dova Pharmaceuticals Inc (Dova) is a clinical-stage pharmaceutical company that develops therapies for the treatment of orphan diseases. The companys lead candidate, Avatrombopag (AVA), a novel, oral thrombopoietin receptor agonist,

USD 250View Report

X4 Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

X4 Pharmaceuticals Inc (X4 Pharma) is a clinical stage biotechnology company that develops novel therapeutics to treat cancer and rare diseases. The companys lead drug candidate, X4P-001-LD, is in Phase

USD 250View Report

Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 250
  • Site Licence    USD 500
  • Enterprise Wide Licence    USD 750
$ 250

Reports Details

Published Date : Dec 2017
No. of Pages :38
Country :United States of America
Category :Pharmaceuticals and Healthcare
Publisher :GlobalData
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment
  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube